SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma eyes to divest manufacturing plant in Ireland: Report

10 Sep 2015 Evaluate

In a bid to control costs that have spiralled since it bought Ranbaxy Laboratories, Sun Pharmaceutical Industries is reportedly looking to divest a manufacturing plant in Ireland.

The world’s fifth largest generic drugmaker has been working on resolving issues at Ranbaxy's India-based drug manufacturing sites, all of which have been banned from exporting to its largest market, the United States, over quality control issues.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable the company to deliver quality products in a timely manner at affordable prices.

Sun Pharma Inds. Share Price

1670.40 -4.80 (-0.29%)
20-Apr-2026 12:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.40
Dr. Reddys Lab 1236.50
Cipla 1234.30
Zydus Lifesciences 942.40
Lupin 2332.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×